Abbvie Inc.

Abb Vie Deutschland Gmbh & Co. Kg

Novartis Ag

Abbott Gmbh & Co Kg

Abbott Laboratories Corporation

Abbvie Deutschland Gmbh and Co Kg

Abbvie Bahamas Limited

Abbvie Ireland Unlimited Company

Ulrich Westedt

Harald Hach

Yi Gao

Ute Lander

Norbert Steiger

Martin Knobloch

Terrence B Mazer

Gunther Berndl

Bernd Liepold

Thomas Kessler

Jörg Breitenbach

Jörg Rosenberg

Normanella Dewille

Nancy E Sever

Ping Tong

Mirko Pauli

Jianwei Wu

Rudolf Schroeder

Adivaraha Jayasankar

Bryan K Erickson

Joerg Ogorka

Simon Kullmann

Gerd Woehrle

Tanja Heitermann

Renato Koenig

Nicoletta Loggia

Ralf Altenburger

Madlen Thiel

Tina Jung

Brent D Sinclair

Jörg Ogorka

Juergen Weis

Dietrich Granzow

Katrin Schneider

Benedikt Steitz

Thomas Mueller

Regina Reul

Constanze Obermiller

Michael Simon

Samuel Kyeremateng

Katharina Asmus

Donghua Zhu

Marius Naris

Colleen Garrett

Youngsuk Heo

Justin Lafountaine

Peter Holig

Eik-Lang Lau

Douglas Wearly

Joerg Breitenbach

Gary Katz

Michael Siimon

The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.

Solid pharmaceutical compositions for treating HCV

A formulation comprising a melt-processed solid dispersion product comprising an active agent, a pharmaceutically acceptable thermoplastic polymer of N-vinyl lactams, and a pharmaceutically acceptable polyvinyl alcohol-polyalkylene glycol graft copolymer. A method for producing said formulation.

Solid retard formulations based on solid dispersions

The invention provides a dosage form, comprising a melt-processed mixture of (a) a pharmaceutically effective amount of imatinib or a salt thereof, (b) at least one polymeric binder, and (c) at least one pharmaceutically acceptable non-ionic surfactant. The invention provides imatinib dosage forms with high drug loading which can be prepared in a simple and efficient manner, imatinib dosage forms from which the active principle is released in an essentially pH-independent fashion, and extended release imatinib dosage forms.

Melt-processed imatinib dosage form

The present invention features solid compositions comprising Compound I, Ior I, or a pharmaceutically acceptable salt thereof, in an amorphous form. In one embodiment, Compound I, Ior I, or a pharmaceutically acceptable salt thereof, is formulated in an amorphous solid dispersion which comprises a pharmaceutically acceptable hydrophilic polymer and preferably a pharmaceutically acceptable surfactant.

Solid compositions

A description is given of a process for the preparation of a pharmaceutical composition of a macrolide antibiotic in essentially noncrystalline form, in which the macrolide antibiotic, a water-swellable polymer and a proton donor are blended in an extruder in the presence of water and forced through a die, the ratio by weight of the sum of macrolide antibiotic, water-swellable polymer and proton donor to water being at least 1:1. The macrolide antibiotic is preferably clarithromycin and the water-swellable polymer is preferably chosen from crosslinked polyvinylpyrrolidone, crosslinked sodium carboxymethylcellulose and crosslinked polyacrylic acid.

Preparation of compositions with essentially noncrystalline embedded macrolide antibiotics

Growing community of inventors

Schriesheim, Germany

Ulrich Westedt